Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

Li Zhou,1 Aaron N. Nguyen,2 Davendra Sohal,1 Jing Ying Ma,2 Perry Pahanish,1,3 Krishna Gundabolu,1 Josh Hayman,1 Adam Chubak,1 Yongkai Mo,1 Tushar D. Bhagat,3 Bhaskar Das,1 Ann M. Kapoun,2 Tony A. Navas,2 Simrit Parmar,3 Suman Kambhampati,4 Andrea Pellagatti,5 Ira Braunchweig,1 Ying Zhang,6 Amittha Wickrema,7 Satyanarayana Medicherla,2 Jacqueline Boulwood,5 Leonidas C. Platanias,8 Linda S. Higgins,2 Alan F. List,9 Markus Bitzer,1 and Amit Verma1,3

1Albert Einstein College of Medicine, Bronx, NY; 2Scios, Fremont, CA; 3University of Texas Southwestern Medical School and Dallas Veterans Affairs Medical Center (VAMC); 4VAMC, Kansas City, MO; 5John Radcliffe Hospital, Oxford, United Kingdom; 6Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD; 7University of Chicago, IL; 8Northwestern University Robert H. Lurie Cancer Center, Chicago, IL; and 9Moffitt Cancer Center, Tampa, FL

MDS is characterized by ineffective hematopoiesis that leads to peripheral cytopenias. Development of effective treatments has been impeded by limited insight into pathogenic pathways governing dysplastic growth of hematopoietic progenitors. We demonstrate that smad2, a downstream mediator of transforming growth factor–β (TGF-β) receptor I kinase (TBRI) activation, is constitutively activated in MDS bone marrow (BM) precursors and is overexpressed in gene expression profiles of MDS CD34+ cells, providing direct evidence of overactivation of TGF-β pathway in this disease. Suppression of the TGF-β signaling by lentiviral shRNA-mediated down-regulation of TBRI leads to in vitro enhancement of hematopoiesis in MDS progenitors. Pharmacologic inhibition of TBRI (alk5) kinase by a small molecule inhibitor, SD-208, inhibits smad2 activation in hematopoietic progenitors, suppresses TGF-β–mediated gene activation in BM stromal cells, and reverses TGF-β–mediated cell-cycle arrest in BM CD34+ cells. Furthermore, SD-208 treatment alleviates anemia and stimulates hematopoiesis in vivo in a novel murine model of bone marrow failure generated by constitutive hepatic expression of TGF-β1. Moreover, in vitro pharmacologic inhibition of TBRI kinase leads to enhancement of hematopoiesis in varied morphologic MDS subtypes. These data directly implicate TGF-β signaling in the pathobiology of ineffective hematopoiesis and identify TBRI as a potential therapeutic target in low-risk MDS. (Blood. 2008;112:3434-3443)

Introduction

The myelodysplastic syndromes (MDSs) are clonal stem cell disorders characterized by cytogenic dysplasia and ineffective hematopoiesis.1-3 Although approximately one third of patients may progress to acute leukemia, refractory cytopenias are the principal cause of morbidity and mortality in patients with MDS.4 In fact, approximately two-thirds of patients present with lower risk disease characterized by hypercellular marrows with increased rates of apoptosis in the progenitor and differentiated cell compartments in the marrow.5-8 Ineffective hematopoiesis arising from abortive maturation leads to peripheral cytopenias. Higher grade or more advanced disease categories are associated with a significant risk of leukemia transformation, with a corresponding lower apoptotic index and higher percentage of marrow blasts.

Cytokines play important roles in the regulation of normal hematopoiesis, and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. Excess production of inhibitory cytokines amplifies ineffective hematopoiesis inherent to the MDS clone. Transforming growth factor–β (TGF-β) is a myelosuppressive cytokine that has been implicated in the hematopoietic suppression in MDS. The plasma levels of TGF-β have been reported to be elevated in some9,11 but not all studies12,13 and are supported by greater TGF-β immunohistochemical staining in selected studies. In addition to direct myelosuppressive effects, TGF-β has also been implicated in the autocrine production of other myelosuppressive cytokines (TNF, IL-6, and IFNγ) in MDS.18 Conflicting data may arise from technical limitations of bone marrow immunohistochemical analyses of a secreted protein as well as the biologic heterogeneity of the disease itself. In addition, plasma levels of TGF-β may not be an accurate reflection of the biologic effects of this cytokine in the MDS bone marrow microenvironment. Thus we investigated the role of TGF-β in MDS by direct examination of receptor signal activation to conclusively determine its role in the pathogenesis of ineffective hematopoiesis in MDS.

Our previous studies have shown that signaling pathways activated by myelosuppressive cytokines can serve as therapeutic targets in low-risk MDS. We showed that interferons (IFNα, IFNβ, and IFNγ), TGF-β, and tumor necrosis factor α (TNFα) can all activate the p38 mitogen-activated protein kinase (MAPK) in primary human hematopoietic progenitors and that activation of p38 is required for myelosuppressive actions of these cytokines on hematopoiesis.19,20 We subsequently confirmed overactivation of p38 MAPK in the bone marrow progenitors of low-risk MDS patients. Our data showed that inhibition of this cytokine-stimulated p38 MAPK pathway partially rescues hematopoiesis in MDS progenitors. This led to a clinical trial of a p38 inhibitor, SCIO-469, in low-risk MDS; the preliminary results have shown modest clinical activity in some cases of lower-risk MDS.21 Having demonstrated that intracellular signaling pathways can serve as...
therapeutic targets in MDS, we decided to directly evaluate TGF-\(\beta\) signaling in MDS. We determined that the smad2 protein is heavily phosphorylated in MDS bone marrow progenitors and is found to be up-regulated in meta-analysis of MDS CD34\(^+\) cell gene expression studies, thereby demonstrating sustained TGF-\(\beta\) signal activation in this disease. We showed that inhibition of the TGF-\(\beta\) receptor I kinase (TBRI) by shRNA suppression or by small molecule inhibitors abrogates smad2 activation and reverses the suppressive effects of TGF-\(\beta\) on hematopoiesis. Most importantly, TBRI inhibition stimulated in vitro hematopoiesis from a variety of MDS progenitors, thus providing a therapeutic rationale for inhibiting TGF-\(\beta\) signaling in this disease.

### Methods

#### Cells lines and reagents human

CD34\(^+\) cells were isolated from bone marrows of healthy or MDS patients, after obtaining informed consent approved by the institutional review boards of University of Texas (UT) Southwestern Medical School (Dallas, TX), the Dallas VAMC, the University of Arizona College of Medicine (Phoenix, AZ), and the University of South Florida (Tampa, FL), and in accordance with the Declaration of Helsinki. Some bone marrow CD34\(^+\) cells from various healthy donors were also obtained from Cambrex (Atlanta, GA). KG-1, K562, and HS-5 cell lines were purchased from ATCC (Manassas, VA). Erythroid progenitors at the colony-forming unit-erythroid (CFU-E) stage of differentiation were grown in cytokine-enriched Iscove modified Dulbecco medium (IMDM) media, similar to our previous studies. Briefer, bone marrow or peripheral blood mobilized CD34\(^+\) cells were immunomagnetically selected and cultured in 15% fetal bovine serum, 15% human serum, IMDM, 10 ng/mL IL-3, 2 units/mL erythropoietin (Epo), and 50 ng/mL stem cell factor (SCF). The cells were fed on days 3 and 6 to maintain an Epo concentration of 2 units/mL. The cells were sorted for glycophorin positivity on day 8 of culture and used for biochemical studies. SCF, thrombopoietin (TPO), Flt-3–ligand (FLT-3L), and Epo were from R&D Systems (Minneapolis, MN). The phos-Smad2 (S465/467), Cdc2, and PCNA antibodies were from Cell Signaling Technology (Beverly, MA); cyclin E2 and Cdc6 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA); and smad2 antibody was from Invitrogen (Carlsbad, CA). TBRI inhibitor SD-208 was provided by Scios (Fremont, CA). SD-208 is a selective 2,4-disubstituted pteridine-derived TGF-\(\beta\) receptor I (TBG-\(\beta\)) kinase inhibitor that exhibits an in vitro specificity for TGF-\(\beta\) (diluent)–treated cells were used as control. Immunoblotting was performed as previously described.

#### Immunohistochemistry

Parafin-mounted bone marrow core biopsy sections from MDS patients and controls were obtained after informed consent. Controls had anemia from non-MDS-related causes. Slides were deparaffinized and hydrated. Mercury pigments from B5 fixative were removed by iodine-sodium thiosulfate sequences. After rinsing 3 times in PBS, all sections were immersed in 3% hydrogen peroxide for 20 minutes at room temperature to completely block endogenous peroxidases. Antigen retrieval (citrate buffer, pH 6.0) was used for all these antibodies. To prevent nonspecific binding with primary antibodies, sections were pretreated with 15% normal goat serum. After 3 washes with PBS, the sections were incubated with primary antibodies overnight at 4°C. The primary antibodies used in this study were rabbit phospho-smad2 polyclonal antibody diluted at 1:1000 dilution (Cell Signaling Technology). After 3 washes with PBS, the sections were incubated with biotinylated goat antirabbit (Chemicon International, Temecula, CA) secondary antibody at 1:2000 dilution at room temperature for 30 minutes. Normal rabbit or mouse IgGs (Santa Cruz Biotechnology) were used as negative controls. All sections were then treated with avidin-biotin-horseradish peroxidase reagents (Vector, Burlingame, CA) and finally stained with diaminobenzidine (Research Genetic, Carlsbad, CA). After several more rinses, the sections were counterstained with hematoxylin and subsequently mounted with Permound (Fisher Scientific) mounting medium. The quantification of p-smad2 staining was analyzed by counting the total number of positively stained cells and by measuring the intensity of the positively stained cells in 5 hot fields (hot field is defined as area of high density of p-smad2 staining) for each patient sample under 400× magnification aided by Image Pro Plus (Media Cybernetics, Bethesda, MD) software. The results were expressed as mean numbers of positively stained cells per field and mean intensity per field for each individual patient sample.

#### ShRNA knockdown experiments

The human lentiviral shRNAmir (pCMV-GIN-Zeo) containing the hairpin sequence TGCTGTGACAGGGAGGTACTATGCGTGGAAGAATTATAGTGACCGACAGATGTATAAGTCTTTACAGTGATACCCTGCCTACTGCTCGGA targeting TGF-\(\beta\)-RI was obtained from Open Biosystems (Huntsville, AL). The scrambled control shRNAmir was cut out from pSM retroviral vector (Open Biosystems) by Xhol and EcoRI and ligated into lentiviral vector and used as a control. Recombinant lentiviruses were produced by transient transfection of the 293FT cells with the transducing vector and 2 packaging vectors: pVSVG, a plasmid expressing the VSVG envelope gene, and pΔ8.9, a plasmid expressing the HIV-1 gag/pol gene. The supernatants were collected 48 hours after transfection. Cell lines HS-5 and K562 were transduced with the virus supernatant in the presence of 8 μg/mL polybrene, and transduced cells were identified by expression of green fluorescent protein (GFP) and sorted by flow cytometry.

### Meta-analysis

National Center for Biotechnology Information’s (NCBI, Bethesda, MD) GEO database was searched for gene expression studies on MDS and normal CD34 cells. A total of 2 MDS datasets with 69 unique MDS CD34\(^+\) studies and 57 normal CD34\(^+\) datasets from 6 studies were identified and downloaded. Fifty-nine MDS samples belonged to low-risk group, whereas 10 belonged to high-grade International Prognostic Scoring System (IPSS) risk group. The data were integrated using UniGene Scoring System (IPSS) risk group. The data were integrated using UniGene

---

*INHIBITION OF TBRI PROMOTES HEMATOPOIESIS IN MDS* 3435

*BLOOD, 15 OCTOBER 2008 • VOLUME 112, NUMBER 8*
CD34+ cell proliferation and cell-cycle assays

CD34+ cells, cultured in IMDM medium (Mediatech, Manassas, VA) containing 15% fetal bovine serum (FBS; HyClone, Logan, UT) and cytokines (50 ng/mL each of SCF, TPO, and FLT-3L), were pretreated with DMSO or 0.5 μM SD-208 for 1 hour before TGF-β1 (0.5 ng/mL final concentration) was added. Cells were cultured for 7 days at 37°C/5% CO2. On days 3, 5, and 7, cell aliquots were taken and viable cell concentration was determined using GuavaViaCount (Guava Technologies, Hayward, CA). The experiment was repeated at least 3 times (using multiple donors of CD34+ cells) with similar results. Cell-cycle distribution of CD34+ cells (gated with PE-conjugated CD34 antibody [BD Biosciences, San Jose, CA]) was determined on day 7 using the APC BrdU Flow Kit and the LSR-II flow cytometer (BD Biosciences) according to the manufacturer’s instructions.

cDNA microarray analysis

CD34+ cells were treated with DMSO or SD-208 in the presence or absence of TGF-β1. After 24 hours, total CD34+ RNA was extracted using Qiagen’s RNeasy kit. Details of microarray and data analysis have been described previously.56 The data were lowest normalized using the maNorm function in microarray package of Bioconductor version 1.5.8 (Fred Hutchinson Cancer Research Center, Seattle, WA). Differential expression values were expressed as the ratio of the median of background-subtracted fluorescent intensity of the experimental RNA to the median of background-subtracted fluorescent intensity of the control RNA.

Murine experiments

Transgenic mice expressing a fusion gene (Alb/TGF) consisting of modified porcine TGF-β1 cDNA under the control of the regulatory elements of the mouse albumin gene55 were used under animal institute–approved protocol. Mice were given SD-208 in 1% methylcellulose solution by gastric lavage using a curved 14-G needle. Blood counts were analyzed by Advia (Bayer) machine. Mice femurs were flushed and bone marrows cells were used for clonogenic assays. Methocult GF M3534 (StemCell Technologies) was used to assess myeloid (granulocyte/macrophage colony-forming unit [CFU-GM]) colony formation, and Methocult SF M3436 was used for erythroid colony (erythroid burst-forming unit [BFU-E]) assessment.

TGF-β gene reporter assay

HS-5 cells were plated in 6-well plates 24 hours before transfection. Cells were transfected in triplicate with SuperFect (Qiagen) according to the manufacturer’s instruction using the reporter plasmid (pGL2-3TP-Lux); plasmids that contain kinase-null TBRI (pRK5-TBRI-KR) were used as positive control.39 pSV-Gal was used to normalize the transfection efficiency. After an overnight incubation, the medium was replaced with serum-free medium with or without SD-208 as necessary for the experiment. After 48 hours, cells were treated with 10 ng/mL TGF-β1. Cells were harvested 24 hours later in reporter lysis buffer (Promega, Madison, WI), and luciferase and β-galactosidase activities were determined using Dual Luciferase System (Promega).

Hematopoietic progenitor cell assays

Hematopoietic progenitor cell formation was determined by clonogenic assays in methylcellulose, as in our previous studies.19,20 All participants in the study signed informed consent, approved by the institutional review board of UT Southwestern and Dallas VA Medical Center. Mononuclear cells were isolated from MDS patient bone marrow aspirates by Ficoll-Hypaque density gradient separation. These cells were cultured in methylcellulose media (Methocult GF H4434; StemCell Technologies) containing recombinant human stem cell factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-3 and erythropoietin. Granulocyte/macrophage colony-forming units (CFU-GMs) and erythroid burst-forming units (BFU-Es) were scored on day 14 of culture.

Results

smad2 is activated in MDS bone marrow precursors

Bone marrows of 20 patients with MDS were assessed for the activation/phosphorylation state of smad2 by immunohistochemistry. Most (16 of 20) patients belonged to lower (low and Int-1 IPSS) risk category of MDS. MDS bone marrow samples were compared with age-matched controls with non-MDS causes of cytopenias (iron deficiency anemia [1], chemotherapy-related anemia [1], hyperplenia [1], drug-induced marrow suppression [1], autoimmune anemia [1], myelofibrosis [1], and unexplained cytopenias in the absence of any dysplasia [2]). Notable activation of smad2 was seen in bone marrow cells of all patients with MDS, (Figure 1A) with a greater number of positively staining cells (Figure 1B) and significantly higher intensity of nuclear staining (Figure 1C) compared with controls. Activation of smad2 was seen in all subtypes of MDS examined (7 with refractory anemia [RA]), 11 with refractory cytopenias with multilineage dysplasia (RCMD), and 2 with refractory anemia with excess blasts [RAEB]). Because smad2 is ubiquitously expressed, we also investigated the phenotypes of bone marrow cells that expressed the activated kinase. Histologic examination revealed that smad2 was activated in hematopoietic progenitors of all lineages including erythroid and myeloid precursors and even megakaryocytes.

Because sustained TGF-β signaling can also lead to up-regulation of smad2 protein, we decided to analyze its expression in a meta-analysis of publicly available microarray studies in MDS. A total of 69 unique MDS patient CD34+ gene expression profiles were obtained from published studies.30,31 integrated using UniGene protein IDs,35 subjected to interarray normalization, and then meta-analysis, available on the website; see the Supplemental Materials link at the top of the online article). Fifty-seven normal CD34+ gene expression profiles were also obtained from a total of 6 studies36-40 and used as controls. This strategy was shown to be a biologically valid strategy for analysis as it was able to cluster datasets based on their cell of origin and phenotype (D.S. and A.V., manuscript submitted). Our analysis of this integrated dataset demonstrated that smad2 gene was greatly up-regulated in low-grade MDS CD34+ cells compared with normal cells (Figure 1D, P < .001). This result is based on other independent studies and confirms our histologic findings, while offering further evidence of overactivated TGF-β signaling in a large number of MDS samples.

Down-regulation of TGF-β receptor I can inhibit smad2 activation in hematopoietic cells and stimulate MDS hematopoiesis

Because smad2 is phosphorylated by TGF-beta receptor I kinase (alk5 kinase, TBRI), lentiviral vectors containing shRNA targeting TBRI were developed (Figure 2A) to determine the biologic role of TGF-smad2 pathway activation in MDS hematopoiesis. The anti-TBRI-shRNA was successfully able to inhibit TBRI expression compared with scrambled control in hematopoietic (K562) and bone marrow stromal (HS-5) cell lines with stable expression of GFP+ lentiviral construct (Figure 2B). Down-regulation of TBRI also led to inhibition of TGF-mediated smad2 activation (Figure 2C), demonstrating a functional level of TBRI inhibition with the
shRNA. Further functional validation showed that introduction of
anti–TBRI-shRNA in primary CD34+/H11001 hematopoietic progenitors
led to their resistance to TGF-β1-mediated suppression of erythroid
colonies (Figure 2D). Hematopoietic progenitors with
GFP+/H11001 TBRI-shRNA expression also formed bigger colonies, again
demonstrating resistance to TGF-β1-mediated antiproliferative sig-

After demonstrating TBRI as a functionally important mediator
of TGF-smad2 signaling, we expressed anti–TBRI-shRNA in
5 primary MDS bone marrow patient samples and performed
clonogenic assays in methylcellulose. Three patients belonged to
RCMD subtype, and 1 each belonged to RA and RAEB subtype.
The patient with RAEB had moderate marrow fibrosis. All MDS
samples demonstrated an increase in erythroid and myeloid colony
formation after anti–TBRI-shRNA expression compared with scrambled control, demonstrating an important functional role of this kinase in hematopoietic suppression seen in MDS (Figure 2F).

**SD-208 is an effective and functionally active inhibitor of TGF-β signaling in hematopoietic cells**

Having demonstrated an important role of TBRI in TGF-smad signaling in hematopoiesis, we next wanted to test the efficacy of SD-208, a novel small molecule pyridopyrimidine inhibitor of TBRI. We first demonstrated that SD-208 was able to potently inhibit smad2 activation in myeloid hematopoietic cell lines KG-1 and K562 as well as in erythroid progenitors derived from primary BM CD34+/H11001 cells (Figure 3 A-C). Because the bone marrow microenvironment plays an important role in cytokine signaling and production in bone marrow failure states, we next tested the efficacy of SD-208 in human bone marrow stromal cells. SD-208 was also able to effectively inhibit TGF-smad2/3–mediated gene transcription in the bone marrow stromal cell line, HS-5. (Figure 3D) Furthermore, functional testing revealed that SD-208 was also able to abrogate the suppressive affects of TGF-β on primary human CD34 proliferation (Figure 4A). These effects were dependent on its ability to block TGF-mediated G0/G1 cell-cycle arrest in these hematopoietic progenitors (Figure 4B,C). Gene expression analysis also supported these findings by demonstrating that cell-cycle progression proteins were not down-regulated by TGF-β in the presence of SD-208 (Table 1). Immunoblotting validated these microarray findings (Figure 4E), thus demonstrating the functional ability of TBRI inhibitor in reversing TGF-mediated actions in hematopoiesis.

**TBRI inhibition can improve anemia in a model of bone marrow failure**

To further examine the effects of TGF-β on bone marrow function, we evaluated the hematopoietic effects of constitutive TGF secretion in a transgenic mouse expressing a fusion gene (Alb/TGF) consisting of modified porcine TGF-β cDNA under the control of the regulatory elements of the mouse albumin gene.38 We determined that these mice become anemic at an early age (3 weeks), and histologic examination of their bone marrows reveals dysplastic megakaryocytes and focal marrow reticulin fibrosis, features commonly seen in human bone marrow failure states such as MDS (Figure 5A,B). These mice were used to determine the specificity...
and efficacy of SD-208 in an in vivo setting. Mice were randomized into treatment or placebo groups on the basis of pretreatment hematocrits. Blood counts were measured after 14 days of oral administration of SD-208 or vehicle. TBRI inhibitor treatment led to significant increase in hematocrit in these mice, demonstrating the specificity of SD-208 in inhibiting TGF-β signaling. Figure 5C). Furthermore, bone marrow progenitors of treated mice showed increased erythroid and myeloid colony forming ability compared with placebo control, thus demonstrating the efficacy of the TBRI inhibitor in rescuing hematopoietic activity in vivo (Figure 5D).

Pharmacologic inhibition of TBRI kinase can stimulate MDS hematopoiesis

Finally, we tested the ability of SD-208 in vitro in 15 MDS bone marrow samples. Most of the patients had low-grade MDS and did not have increased blast counts (Table 2). Mononuclear cells were grown in methylcellulose with cytokines in the presence and absence of various doses of SD-208. Consistent with results seen with siRNAs, treatment with the TBRI inhibitor (Figure 6) resulted in a significant increase in erythroid (BFU-E) and myeloid (CFU–granulocytic monocytic) colony numbers (Figure 6A). These results point to a high therapeutic potential of TBRI inhibition in low-grade MDS.

Discussion

Progress in the discovery of disease-selective treatments for MDS has been challenged by the limited insight into molecular pathogenesis of the ineffective hematopoiesis seen in these disorders. Our work has shown that TGF-smad2 pathway is commonly overactivated in a variety of subtypes of MDS. Inhibition of the TGF-β receptor 1 kinase (TBRI) blocks smad2 activation and promotes MDS hematopoiesis in vitro, suggesting that TGF-β–smad2 signaling pathway is a functionally important inhibitory pathway in MDS.

Transforming growth factor–beta (TGF-β) is an important physiologic regulator of cell proliferation and differentiation. TGF-β has been shown to affect both early and late stages of hematopoiesis and generally leads to suppressive effects on erythroid and myeloid cell proliferation. Deregulation of TGF-β signaling has been implicated in a variety of carcinogenesis and metastasis models, illustrating an important biologic role in oncogenesis. Because MDS is a preleukemic condition characterized by dysplastic hematopoiesis, earlier studies have also examined the role of TGF-β in this disease. Most reports to date have relied upon immunohistochemical detection of TGF-β in patient bone marrows or measurement of TGF-β levels in patient plasma. Some of these studies showed increased TGF-β in MDS, whereas some did not observe any correlation. As local concentrations of cytokines can be more informative than serum concentrations and immunohistochemical detection of cell surface proteins in bone marrow sections has technical limitations, we focused our studies on direct evaluation of nuclear smad2 phosphorylation in MDS bone marrows. Smad2 activation and nuclear translocation are specific and accurate markers of TGF-β signaling, and Smad2 up-regulation occurs with sustained TGF-β signaling. Thus, our results are the first to directly show evidence that TGF-β signaling is a common pathway activated in MDS and indicate that a downstream signaling biomarker can identify a valid therapeutic target.

Because MDS is a heterogeneous disease, we validated our findings in a larger number of MDS samples. We devised a meta-analytic approach using publicly available gene expression data to test our hypothesis. Recent publications have concluded that microarray data generated in different laboratories and different platforms can be compared after adequate integration and normalization. Our database covered 6 independent studies and provides further validation of our findings that is hard to achieve with single-center studies in a complex disease such as MDS. We hope that creation of this database will also help other MDS investigators.

Our findings are consistent with other work that has been done in defining molecular pathways in MDS. Our earlier data demonstrated that cytokine signaling cascades such as p38 MAPK can be functionally important in regulating hematopoietic failure in MDS. It has also been shown that TGF-β can activate p38 and other MAP kinase pathways. Thus our earlier results can in part be explained by overactivated TGF-β signaling in MDS. A recent clinical trial evaluating thalidomide in MDS observed that patients with increased red cell counts after treatment had a significant decrease in TGF-β levels. Even though this was a small study it reinforces our findings, suggesting an important role of TGF-β signaling in ineffective hematopoiesis. In addition, our data point to...
a greater role of TGF-β–suppressive signaling in low-grade MDS. The bone marrow at this stage of the disease is hypercellular and is characterized by increased rates of apoptosis. At this stage of the disease, both normal and cytogenetically abnormal hematopoietic clones are found to exist in the marrow.50 With disease progression toward high-risk stages, normal progenitors gradually diminish, resulting in a bone marrow composed mainly of the resistant abnormal clones with an increased percentage of myeloblasts. These observations in combination with our data may allude to a pathogenic role of TGF-β in suppressing hematopoiesis in normal clonal progenitors in low-grade MDS. As preponderance of leukemic clones seen in higher grade MDS is characterized by relative resistance to suppressive effects of TGF-β,41,51-53 the therapeutic efficacy of TBRI inhibitors may be greater in low-grade disease subtypes.

Ineffective hematopoiesis is the cause of most of morbidity in patients with low-risk MDS. Two-thirds of all MDS cases are at the low-risk stage, have a lower chance of progressing to leukemia, and suffer problems mainly associated with low blood counts. Thus strategies aimed at raising blood counts are needed at this stage. The erythroid lineage is the most commonly affected hematopoietic lineage in MDS. TGF-β has recently been shown to regulate both primitive and late stages of erythropoiesis,54 by distinct molecular processes. After smad2/3 phosphorylation by the TBRI kinase, these proteins associate with partner smads and other proteins to bind distinct DNA sequences and regulate different biologic functions. It has recently been shown that smad2-smad4 complex enters the nucleus and negatively regulates suppression of primitive erythropoiesis, whereas the smad2-TIF complex can regulate late stages of erythroid differentiation.54 Thus TBRI-

Table 1. Cell-cycle progression genes down-regulated by TGF-β

<table>
<thead>
<tr>
<th>Clone ID</th>
<th>TGF-β1 (24 h)*</th>
<th>SD-208 plus TGF-β1 (24 h)</th>
<th>Symbol</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>P01125_G01</td>
<td>−2.3</td>
<td>1.8</td>
<td>CDC2</td>
<td>Cell division 2</td>
</tr>
<tr>
<td>P01066_F04</td>
<td>−2.6</td>
<td>2.0</td>
<td>CDC6</td>
<td>Cell division 6</td>
</tr>
<tr>
<td>P01091_D07</td>
<td>−2.0</td>
<td>2.2</td>
<td>CDC7</td>
<td>Cell division 7</td>
</tr>
<tr>
<td>P01090_D07</td>
<td>−2.0</td>
<td>1.9</td>
<td>CDC45L</td>
<td>Cell division 4S-like</td>
</tr>
<tr>
<td>P01077_E02</td>
<td>−3.0</td>
<td>2.2</td>
<td>CCNA2</td>
<td>Cyclin A2</td>
</tr>
<tr>
<td>P01093_D10</td>
<td>−1.9</td>
<td>1.9</td>
<td>CCNE1</td>
<td>Cyclin E1</td>
</tr>
<tr>
<td>P01113_A07</td>
<td>−2.1</td>
<td>2.0</td>
<td>CCNE2</td>
<td>Cyclin E2</td>
</tr>
<tr>
<td>P01071_H02</td>
<td>−2.3</td>
<td>2.1</td>
<td>PCNA</td>
<td>Proliferating cell nuclear antigen</td>
</tr>
<tr>
<td>P01071_E06</td>
<td>−1.9</td>
<td>2.0</td>
<td>RFC3</td>
<td>Replication factor C3</td>
</tr>
<tr>
<td>P01102_D08</td>
<td>−2.1</td>
<td>1.8</td>
<td>E2F1</td>
<td>E2F transcription factor 1</td>
</tr>
</tbody>
</table>

*Fold change of gene expression over control unstimulated CD34+ cells.
dependent smad2 overactivation in MDS can affect different facets of erythropoiesis and can be abrogated by inhibition of the alk5 kinase.

In addition to MDS, TGF-β has also been implicated in the pathobiology of idiopathic myelofibrosis (IMF). Due to the fibrogenic actions of TGF-β, oversecretion of this cytokine has been

Table 2. Patient characteristics

<table>
<thead>
<tr>
<th>Age, y/sex</th>
<th>WBC count, x10^9/L</th>
<th>Hgb level, g/dL</th>
<th>Plt count, x10^9/L</th>
<th>Cytogenetics</th>
<th>Path</th>
<th>IPSS</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>89/M</td>
<td>4.6</td>
<td>9.2</td>
<td>169</td>
<td>N</td>
<td>CMML</td>
<td>0</td>
<td>Low</td>
</tr>
<tr>
<td>71/M</td>
<td>3.9</td>
<td>8.1</td>
<td>154</td>
<td>N</td>
<td>RA</td>
<td>0</td>
<td>Low</td>
</tr>
<tr>
<td>76/M</td>
<td>6</td>
<td>7</td>
<td>137</td>
<td>N</td>
<td>RA</td>
<td>0</td>
<td>Low</td>
</tr>
<tr>
<td>75/M</td>
<td>3.4</td>
<td>10</td>
<td>146</td>
<td>N</td>
<td>RA</td>
<td>0</td>
<td>Low</td>
</tr>
<tr>
<td>69/M</td>
<td>2.1</td>
<td>9.6</td>
<td>120</td>
<td>N</td>
<td>RCMD</td>
<td>0.5</td>
<td>Int-1</td>
</tr>
<tr>
<td>65/M</td>
<td>2.4</td>
<td>10.8</td>
<td>90</td>
<td>N</td>
<td>RCMD</td>
<td>0.5</td>
<td>Int-1</td>
</tr>
<tr>
<td>58/M</td>
<td>3</td>
<td>12</td>
<td>106</td>
<td>N</td>
<td>RA</td>
<td>0.5</td>
<td>Int-1</td>
</tr>
<tr>
<td>88/M</td>
<td>2.4</td>
<td>8.3</td>
<td>155</td>
<td>N</td>
<td>RCMD</td>
<td>0.5</td>
<td>Int-1</td>
</tr>
<tr>
<td>77/M</td>
<td>2</td>
<td>12</td>
<td>174</td>
<td>N</td>
<td>RCMD</td>
<td>0.5</td>
<td>Int-1</td>
</tr>
<tr>
<td>76/M</td>
<td>5.2</td>
<td>9.4</td>
<td>41</td>
<td>t(11:14)</td>
<td>RCMD</td>
<td>1</td>
<td>Int-1</td>
</tr>
<tr>
<td>70/M</td>
<td>4.7</td>
<td>12</td>
<td>20</td>
<td>del 20q</td>
<td>RAEB</td>
<td>1</td>
<td>Int-1</td>
</tr>
<tr>
<td>78/M</td>
<td>0.6</td>
<td>6</td>
<td>30</td>
<td>del 16 (q22)</td>
<td>RCMD</td>
<td>1.5</td>
<td>Int-2</td>
</tr>
<tr>
<td>48/F</td>
<td>5.2</td>
<td>8.4</td>
<td>95</td>
<td>–1q, –11q</td>
<td>RAEB</td>
<td>1.5</td>
<td>Int-2</td>
</tr>
<tr>
<td>73/M</td>
<td>1.2</td>
<td>9.4</td>
<td>88</td>
<td>–20q, iso 17q</td>
<td>RCMD</td>
<td>2</td>
<td>Int-2</td>
</tr>
<tr>
<td>65/F</td>
<td>3.1</td>
<td>8.3</td>
<td>54</td>
<td>N</td>
<td>RAEB</td>
<td>1.5</td>
<td>Int-2</td>
</tr>
</tbody>
</table>

WBC indicates white blood cell; Hgb, hemoglobin; Plt, platelet; Path, pathological condition; and CMML, chronic myelomonocytic leukemia
correlated with marrow fibrosis seen in IMF.\textsuperscript{55,56} In addition, myelofibrosis seen after thrombopoietin overexpression in mice can be abrogated by depletion of TGF-\(\beta\)-1 by a soluble receptor, suggesting that TGF-\(\beta\) secretion is an important downstream effector of marrow fibrosis in various cytokine-induced models of hematopoietic failure.\textsuperscript{57} These data coupled with our findings provide a rationale for using inhibitors of TGF-\(\beta\) (including TBRI inhibitors) in other bone marrow failure syndromes. TBRI selectively participates in TGF-\(\beta\) signaling, whereas other activin-like and TGF-\(\beta\) receptors can also participate in BMP and activin ligand signaling\textsuperscript{49,53} and thus provide selective therapeutic efficacy. SD-208 is a selective 2,4-disubstituted pteridine-derived TGF-\(\beta\)RI kinase inhibitor\textsuperscript{23-28} that has demonstrated specificity for this kinase. In addition, other TBRI inhibitors are in development\textsuperscript{27,59} for various other indications such as chronic renal diseases. Our findings provide a preclinical rationale for bringing these agents into clinical trials for MDS.

**Acknowledgments**

This work was supported by National Institutes of Health (NIH, Bethesda, MD) 1R01HL082946-01 and Community Foundation of Southeastern Michigan (Detroit) J. P. McCarthy fund award (A.V.); by NIH RO1 AG029138 (L.C.P.); and by Immunooncology Training Program T32 CA009173 (L.Z.).

**Authorship**


Correspondence: Amit Verma, Chanin 302B, Albert Einstein Cancer Center, 1300 Morris Park Ave, Bronx, NY 10461; e-mail: averma@aecom.yu.edu.

**References**

27. Akhurst RJ. Large- and small-molecule inhibitors...


